SCHEMBL16665707

SCHEMBL16665707

N#Cc1cc(-c2n[nH]c3ncnc(N)c23)cc(O)c1F

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 17/20 0.40
EGFR P00533 16/20 0.40
PIK3CA P42336 16/20 0.40
PIK3CB P42338 16/20 0.40
PIK3CG P48736 16/20 0.40
PRKDC P78527 16/20 0.40
ABL1 P00519 15/20 0.40
HCK P08631 15/20 0.40
SRC P12931 15/20 0.40
MTOR P42345 15/20 0.40
KDR P35968 14/20 0.40
EPHB4 P54760 14/20 0.40
PI4KB Q9UBF8 8/20 0.36
BTK Q06187 1/20 0.35
MAP4K4 O95819 1/20 0.35
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CCNA1 P78396 1/20 0.33
MAP2K1 Q02750 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16655157 0.84 PIK3CD (0.47) PIK3CDEGFRPIK3CAPIK3CBPIK3CG
SCHEMBL23917514 0.83 PIK3CG (0.46) PIK3CDEGFRPIK3CAPIK3CBPIK3CG
SCHEMBL16665741 0.80 PIK3CD (0.36) PIK3CDEGFRPIK3CAPIK3CBPIK3CG
SCHEMBL16665713 0.79 PIK3CD (0.36) PIK3CDEGFRPIK3CAPIK3CBPIK3CG
SCHEMBL20093476 0.77 VRK1 (0.41) PIK3CDEGFRPIK3CAPIK3CBPIK3CG
SCHEMBL11928101 0.76 PIK3CD (0.56) PIK3CDEGFRPIK3CAPIK3CBPIK3CG
SCHEMBL23917249 0.76 PIK3CD (0.34) PIK3CDEGFRPIK3CAPIK3CBPIK3CG
SCHEMBL16654164 0.75 PIK3CD (0.36) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL16065725 0.75 PIK3CD (0.53) PIK3CDEGFRPIK3CAPIK3CBPIK3CG
SCHEMBL21467053 0.74 PIK3CG (0.52) PIK3CDEGFRPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US disclosed
WO-2015058084-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317140-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB PIK3CD 2/4885EGFR 828/4885PIK3CA 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.